Dolton, Garry, Thomas, Hannah, Tan, Li Rong, Rius Rafael, Cristina  ORCID: https://orcid.org/0000-0002-1896-1649, Doetsch, Stephanie, Ionescu, Giulia-Andreea, Cardo, Lucia F., Crowther, Michael D., Behiry, Enas, Morin, Théo, Caillaud, Marine E., Srai, Devinder, Parolini, Lucia, Hasan, Md Samiul, Fuller, Anna, Topley, Katie, Wall, Aaron, Hopkins, Jade R., Omidvar, Nader, Alvares, Caroline  ORCID: https://orcid.org/0000-0003-4391-9802, Zabkiewicz, Joanna  ORCID: https://orcid.org/0000-0003-0951-3825, Frater, John, Szomolay, Barbara  ORCID: https://orcid.org/0000-0002-5375-5533 and Sewell, Andrew K.  ORCID: https://orcid.org/0000-0003-3194-3135
      2025.
      
      MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-α chain.
      The Journal of Clinical Investigation
      135
      
        (1)
      
      
      , e181895.
      10.1172/JCI181895
    
  
    
    
       
    
  
  
       | 
    
| 
        
  
  
       | 
    
        
  
  
      Halilovic, Melisa, Abdelsalam, Mohamed, Zabkiewicz, Joanna  ORCID: https://orcid.org/0000-0003-0951-3825, Lazenby, Michelle, Alvares, Caroline  ORCID: https://orcid.org/0000-0003-4391-9802, Schmidt, Matthias, Brenner, Walburgis, Najafi, Sara, Oehme, Ina, Hieber, Christoph, Zeyn, Yanira, Bros, Matthias, Sippl, Wolfgang and Krämer, Oliver H.
      2024.
      
      Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.
      Leukemia
      38
      
      , pp. 2561-2572.
      
      10.1038/s41375-024-02405-5
    
  
    
    
       
    
  
  
       | 
    
| 
        
  
  
       | 
    
        
  
  
      Jonas, Brian A., Hou, Jing-Zhou, Roboz, Gail J., Alvares, Caroline L.  ORCID: https://orcid.org/0000-0003-4391-9802, Jeyakumar, Deepa, Edwards, John R., Erba, Harry P., Kelly, Richard J., Röllig, Christoph, Fiedler, Walter, Brackman, Deanna, Siddani, Satya R., Chyla, Brenda, Hilger-Rolfe, Jacqueline and Watts, Justin M.
      2023.
      
      A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
      Hematological Oncology
      41
      
        (4)
      
      , pp. 743-752.
      
      10.1002/hon.3159
    
  
    
    
       
    
  
  
       | 
    
| 
        
  
  
       | 
    
        
  
  
      Chiriches, Claudia  ORCID: https://orcid.org/0000-0003-3758-1892, Nicolaisen, Nathalie, Wieske, Maria, Elhaddad, Heba, Mehmetbeyoglu, Ecmel, Alvares, Caroline  ORCID: https://orcid.org/0000-0003-4391-9802, Becher, Dörte, Hole, Paul, Ottmann, Oliver Gerhard  ORCID: https://orcid.org/0000-0001-9559-1330 and Ruthardt, Martin  ORCID: https://orcid.org/0000-0003-1021-3811
      2022.
      
      Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.
      PLoS Genetics
      18
      
        (10)
      
      
      , e1010463.
      10.1371/journal.pgen.1010463
    
  
    
    
       
    
  
  
       | 
    
| 
        
  
  
       | 
    
        
  
  
      Zabkiewicz, Joanna  ORCID: https://orcid.org/0000-0003-0951-3825, Lazenby, Michelle, Edwards, Gareth, Bygrave, Ceri A., Omidvar, Nader, Zhuang, Lihui, Knapper, Steve  ORCID: https://orcid.org/0000-0002-6405-4441, Guy, Carol, Hills, Robert K.  ORCID: https://orcid.org/0000-0003-0166-0062, Burnett, Alan K. and Alvares, Caroline L.  ORCID: https://orcid.org/0000-0003-4391-9802
      2020.
      
      Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia.
      British Journal of Haematology
      191
      
        (2)
      
      , pp. 231-242.
      
      10.1111/bjh.16665
    
  
    
    
       
    
  
  
       | 
    
| 
        
  
  
       | 
    

							

 Up a level